New cell therapy takes aim at Hard-to-Treat multiple myeloma

NCT ID NCT07294625

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new cell therapy called LVIVO-TaVec200 in 36 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the therapy behaves in the body. Participants receive the treatment and are closely monitored for side effects and signs of disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, China

Contact
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China

Contact
The Affiliated Hospital of XUZHOU Medical University
NOT_YET_RECRUITING

Xuzhou, Jiangsu, China

Contact
The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, China

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING

Xi’an, Shanxi, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.